KALM Therapeutics
Huntsville, US · Founded 2024 · Delaware corporation
Founders & leadership
CS
Chris SeibertExecutive
AS
Anuj SinghalExecutive
Reported raises · per SEC filings
Form D private placements$590.4K disclosed across 1 round · 2024
▶$590.4KraisedAug 2024 · 14 investors · BiotechnologyRule 506(b)
▶$590.4KraisedAug 2024 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chris SeibertExecutive Officer, Director
- Anuj SinghalExecutive Officer, Director
- Offering amount
- $590.4K
- Amount sold
- $590.4K
- Minimum investment
- $25K
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- How much funding has KALM Therapeutics raised?
- KALM Therapeutics has disclosed $590.4K raised across 1 round.
- Where is KALM Therapeutics headquartered?
- KALM Therapeutics is headquartered in Huntsville, US.